Cookies on our website

We use cookies on our website. To learn more about cookies, how we use them on our site and how to change your cookie settings please view our cookie policy.

Read more Close
Skip Ribbon Commands
Skip to main content
Sign In

Publications

From Takeda to Teva v Merck: Are We Treading the Right Path on Combination Product SPCs? (Part 2)

 

02 November 2017

Nicola Dagg and Steve Baldwin, along with Dr Tony Rollins, deal with SPCs for combination products and focus on the development of the law (in particular as regards Articles 3(a) and (c) of the SPC Regulation) from the Takeda case through to the recent UK decisions in Teva v Gilead and Teva v Merck.  As with Part 1 of this series, this article includes a data analysis of combination SPCs on the UKIPO’s register between 1994-2011 and how Life Sciences companies have approached the filing of SPCs for combination products in practice.

To read the full article click here.

This material was first published by Thomson Reuters and Contributors in Nicola Dagg, Steve Baldwin and Dr Tony Rollins , “From Takeda to Teva v Merck: Are We Treading the Right Path on Combination Product SPCs? (Part 2)”, (2017) 39 (11) E.I.P.R. 697-704, and is reproduced by agreement with the Publishers.

 

 

Publications search




Related expertise

 
 

Client alerts

Already signed up for Client alerts? Click here to access your portal



  • Add comment (optional)